The estimated Net Worth of Tushar Misra is at least $524 Thousand dollars as of 13 January 2024. Dr Misra owns over 8,541 units of Mersana Therapeutics Inc stock worth over $37,742 and over the last 3 years he sold MRSN stock worth over $0. In addition, he makes $485,891 as SVP & Chief Manufacturing Officer at Mersana Therapeutics Inc.
Dr has made over 4 trades of the Mersana Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 8,541 units of MRSN stock worth $15,118 on 13 January 2024.
The largest trade he's ever made was exercising 8,541 units of Mersana Therapeutics Inc stock on 13 January 2024 worth over $15,118. On average, Dr trades about 3,214 units every 74 days since 2021. As of 13 January 2024 he still owns at least 21,323 units of Mersana Therapeutics Inc stock.
You can see the complete history of Dr Misra stock trades at the bottom of the page.
Dr. Tushar Misra Ph.D. is the SVP & Chief Manufacturing Officer at Mersana Therapeutics Inc.
As the SVP & Chief Manufacturing Officer of Mersana Therapeutics Inc, the total compensation of Dr D at Mersana Therapeutics Inc is $485,891. There are 10 executives at Mersana Therapeutics Inc getting paid more, with Anna Protopapas having the highest compensation of $1,739,800.
Dr D is 61, he's been the SVP & Chief Manufacturing Officer of Mersana Therapeutics Inc since . There are 3 older and 17 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Tushar's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: